Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/429—Thiazoles condensed with heterocyclic ring systems
  • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/429—Thiazoles condensed with heterocyclic ring systems
  • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
  • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• This invention relates to pharmaceutical compositions, and more specifically to a liquid premix formulation of piperacillin sodium and tazobactam sodium.
• the liquid premix formulation is suitable for intravenous administration and has a viable shelf-life.
• Polymicrobial infections often include pathogens that produce beta-lactamase enzymes. These enzymes commonly cause resistance to penicillins and cephalosporins. Without treatment these enzymes would multiply and thrive unimpeded, with serious or critical consequences to the patient.
• the piperacillin component offers the safety and efficacy of a broad- spectrum beta-lactam antibiotic.
• Tazobactam reduces the vulnerability of the piperacillin to the bacteria that produce beta-lactamase enzymes. Basically, the tazobactam permanently inactivates beta-lactamases, allowing the piperacillin component to destroy susceptible bacteria.
• Zosyn ® is supplied in a lyophilized form and therefore must be reconstituted prior to intravenous administration. Zosyn ® is a relatively potent antibiotic.
• Escherichia coli skin and skin structure infections, including cellulitits, cutaneous abscesses and ischemic/diabetic foot infections due to Staphylococcus aureus; and gynecologic infections, specifically postpartum endometritis or pelvic inflammatory disease due to Escherichia coli.
• skin and skin structure infections including cellulitits, cutaneous abscesses and ischemic/diabetic foot infections due to Staphylococcus aureus
• gynecologic infections specifically postpartum endometritis or pelvic inflammatory disease due to Escherichia coli.
• the seriousness of these infections highlights the need for a readily available and dependable treatment
• the admixing required by the lyophilized vial product is a skilled pharmaceutical procedure that must be performed using aseptic techniques to ensure product quality. This step creates the possibility of contamination and dosage miscalculation. It also adds to the cost of preparing the Zosyn ® for administration.
• the laborious and difficult technique of lyophilizing and reconstituting the drug is addressed in U.S. Patent No. 5,763,603 to Trickes. While the Trickes reference does teach a process of increasing the stability of tazobactam, such is accomplished by crystallization rather than in a buffered pH solution.
• the reconstituted product is reflected in its short refrigerated shelf life.
• the reconstituted product remains stable and commercially viable for only seven days while refrigerated according to the manufacturer's product labeling (See also Physicians' Desk Reference, Medical Economics Company, Inc., pp. 1434-37 (52 ed., 1998)).
• the short shelf life and the reconstitution step may also lead to increased waste disposal as the components required to prepare the reconstituted solution, such as vials, needles and bags, as well as unused portions of the product, must be properly discarded.
• lyophilized powder vial product has a pH more acidic than 6.5. This acidic condition increases the potential for hemolysis and pain to the patient during infusion.
• the formulations of the present invention overcome the disadvantages of the reconstituted product as they are premixed and stable for longer periods at refrigerated temperature. Additionally, any potential for problems of contamination, needle sticks, increased waste, and dosage calculation errors are avoided, as medical personnel can simply use a prepared bag of the present formulations.
• a new liquid form of premixed piperacillin for use in parenteral administration to fight polymicrobial infection in patients is disclosed.
• many disadvantages of the prior art can be avoided.
• Such disadvantages include possible contamination, increased waste disposal, dosage calculation errors, and drug instability to name a few.
• the piperacillin, as piperacillin sodium in a solution of suitable liquid, is brought within a suitable pH range.
• the pH, and therefore the stability of the solution can be maintained by buffering the formulation with a suitable quantity of a citrate.
• an effective amount of tazobactam, as tazobactam sodium is included with the buffered piperacillin solution.
• the pH of this embodiment is also maintained within a particular range.
• any of the previous embodiments may be made physiologically iso-osmotic (a.k.a., isosmotic) with the addition of dextrose hydrous or dextrose anhydrous.
• the stability of the formulations allows the present invention to be stored for at least nine months at -20 °C or below. Before use the frozen formulation is thawed and remains viable for one day at room temperature. Alternatively, the formulations may be stored at a refrigerated temperature (5°C ⁇ 3 °C) for as long as 14 days and remain viable according to the premix product labeling. This is enhanced stability compared to the reconstituted vial product, which is only viable for seven (7) days while refrigerated according to the manufacturer's product labeling.
• the present inventive formulations offer a number of advantages over other forms of piperacillin and piperacillin/tazobactam administration.
• the premixed solution demonstrates long-term stability and enhanced shelf life when prepared at a physiologically suitable pH range.
• the long-term stability of piperacillin in solution was not known before the present invention.
• the stability of the formulation is achieved by buffering the solution with citrate to maintain the pH range.
• Piperacillin free acid is the preferred source of piperacillin for use in the present invention.
• the free acid is converted to the sodium salt during the formulation process.
• Piperacillin sodium is derived from D(-)- - aminobenzylpenicillin.
• piperacillin sodium is sodium (2S, 5R, 6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-l-piperazinecarboxamido)-2-phenylacetamido]-3,3- dimethyl-7-oxo-4-thia-l-azabicyclo(3.2.0) heptane-2-carboxylate, with a chemical formula of C 23 H 26 N 5 NaO 7 S and a molecular weight of 539.6.
• Piperacillin free acid was obtained in powder form from Wyeth-Ayerst.
• the piperacillin free acid is preferably mixed with a quantity of deionized water, and neutralized with sodium bicarbonate or other suitable agents, to bring the concentration of the solution within the preferred range of 20 to 80 mg/ml, more preferably within the range of 30 to 70 mg/ml, and most preferably within the range of 38 to 62 mg/ml or any combination or subcombination of ranges therein.
• Tazobactam free acid is the preferred source of tazobactam for use in the present invention.
• the free acid is converted to the sodium salt during the formulation process.
• Tazobactam sodium a derivative of the penicillin nucleus, is a penicillanic acid sulfone. Its chemical name is sodium (2S, 3S, 5R)-3-methyl-7-oxo- 3-( 1 H- 1 , 2, 3-triazol- 1 -ylmethyl)-4-thia- 1 -azabicyclo-(3.2.0)heptane-2-carboxylate-4, 4-dioxide.
• the chemical formula for tazobactam sodium is C 10 H ⁇ N 4 NaO 5 S and the molecular weight is 322.3.
• Tazobactam free acid was supplied in powdered form through Wyeth-Ayerst.
• Tazobactam free acid is to be added to the piperacillin solution to create a concentration of tazobactam sodium to within a preferable range of 0.0 to 9.0 mg/ml, more preferably within the range of 4.0 to 8.0 mg/ml, and most preferably within the range of 4.8 to 7.8 mg/ml, or any range or subcombination of ranges therein.
• the total concentration of piperacillin sodium and tazobactam sodium in solution is preferably within the range of 20 to 89 mg/ml. More preferably the total concentration is within the range of 34 to 78 mg/ml, and most preferably within the range of 42.8 to 69.8 mg/ml, or any range or subcombination of ranges therein. These quantities allow for an effective amount of piperacillin or piperacillin/tazobactam to be delivered in common dosage amounts of 50 to 250 ml.
• the resulting piperacillin or piperacillin/tazobactam solution is then brought to within a preferred pH range of 6.1 to 6.9, and more preferably within the range of 6.3 to 6.7.
• the pH of the solution is about 6.5.
• Hydrochloric acid or other suitable acid can be used to adjust the pH downward, and sodium bicarbonate, or other suitable base, can be used to adjust the pH upward
• the solution is buffered with citrate or other suitable buffers.
• Citrate is the preferred buffer because it can maintain the pH of the solution without significant drag degradation.
• the pH cannot be maintained in the frozen state (See "Effect Of Freezing On The pH And Composition Of Sodium And Potassium Phosphate Solutions: The reciprocal system KH 2 PO 4 -Na 2 HPO 4 -H 2 O," L. Van den Berg and D. Rose, Arch.
• a buffer for controlling the pH to enhance stability.
• a suitable amount of sodium citrate used to buffer the formulation controls the pH for maximum stability without significantly catalyzing or degrading the drug, or causing pain to the patient upon infusion.
• Sodium citrate dihydrate is the preferred form for the buffer used in the present invention.
• the amount of sodium citrate dihydrate is preferably within the range of 1 to 4 mg/ml, more preferably within the range of 1.5 to 3.5 mg/ml, and most preferably within the range of 1.8 to 3.2 mg/ml or any range or subcombination of ranges therein.
• dextrose hydrous or anhydrous can be used in the present invention.
• concentration of the dextrose hydrous is within the preferred range of 5 to 30 mg/ml, and more preferably within the range of 6 to 22 mg/ml or any combination or subcombination or ranges therein.
• Suitable containers include those sold by Baxter under the tradename GALAXY ® .
• the containers are then stored in a freezer at -20 °C or lower. Studies have shown that the formulations of the present invention remain viable for at least nine months while frozen.
• the frozen containers should be thawed in a conventional manner.
• the formulations will remain viable at room temperature for one day after removal from the freezer.
• the containers may be refrigerated at about 5 ° ( ⁇ 3 °C) for as much as 14 days.
• Formulations were either unbuffered or buffered with sodium citrate dihydrate. Various solution pHs were evaluated as well. Preferred formulations were stored for up to nine months frozen.
• the solution pH could be varied, but remain in the zone of the desired long-term drug stability period; the dextrose concentration can be varied slightly and still allow the formulation to be isosmotic; and the citrate buffer concentration can be varied, but retain sufficient buffer capacity without causing pain on infusion.
• the examples given herein are intended to illustrate the invention and not in any sense to limit the manner in which the invention can be practiced.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Biochemistry (AREA)
• Dermatology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Plural Heterocyclic Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22968672

Family Applications (1)

Country Status (12)

Cited By (8)

Families Citing this family (13)

Family Cites Families (19)

• 1999
  • 1999-02-22 US US09/255,513 patent/US6207661B1/en not_active Expired - Lifetime
• 2000
  • 2000-01-21 PT PT00906992T patent/PT1154770E/pt unknown
  • 2000-01-21 CA CA002361392A patent/CA2361392C/en not_active Expired - Lifetime
  • 2000-01-21 ES ES00906992T patent/ES2322790T3/es not_active Expired - Lifetime
  • 2000-01-21 DE DE60041868T patent/DE60041868D1/de not_active Expired - Lifetime
  • 2000-01-21 JP JP2000600646A patent/JP2002537335A/ja not_active Withdrawn
  • 2000-01-21 EP EP00906992A patent/EP1154770B1/en not_active Expired - Lifetime
  • 2000-01-21 DK DK00906992T patent/DK1154770T3/da active
  • 2000-01-21 AT AT00906992T patent/ATE426404T1/de active
  • 2000-01-21 AU AU28562/00A patent/AU2856200A/en not_active Abandoned
  • 2000-01-21 WO PCT/US2000/001588 patent/WO2000050035A2/en not_active Ceased
• 2006
  • 2006-09-04 JP JP2006239375A patent/JP4820244B2/ja not_active Expired - Lifetime
• 2009
  • 2009-04-13 CY CY20091100433T patent/CY1108966T1/el unknown

Also Published As

Similar Documents

Legal Events